Studies measuring TF using FCM
| Disease/treatment . | Sample type . | TF antibody . | Results . | Reference . |
|---|---|---|---|---|
| Cancer | Plasma | CD142-PE (HTF-1), BD | Higher levels of TF-positive EVs in samples from patients with cancer compared with controls. Higher levels of TF-positive EVs in samples from patients with cancer with VTE compared with without VTE | 68 |
| Atorvastatin treatment | Plasma | CD142-PE (HTF-1), BD | Higher levels of TF-positive EVs during active treatment compared with nontreatment | 69 |
| Deep venous thrombosis | EV | CD142-FITC (VIC7), BioMedica Diagnostics | Higher levels of TF-positive EVs in samples from patients with VTE compared with controls | 70 |
| Statin therapy | EV | CD142-FITC (VD8), BioMedica Diagnostics | Statin therapy decreased the levels of TF-positive EVs | 71 |
| Lung cancer | Plasma | CD142-FITC, BioMedica Diagnostics | Levels of TF-positive EVs predicted distant metastasis | 72 |
| Cardiovascular risk | EV | CD142-FITC (VD8), BioMedica Diagnostics | Levels of TF-positive EVs correlated with lipid-rich atherosclerotic plaques | 73 |
| Cardiovascular risk | EV | CD142-FITC (VD8), BioMedica Diagnostics | Levels of TF-positive EVs were higher in patients with high cardiovascular risk than patients without risk | 74 |
| Type 2 diabetes | EV | CD142-PE (HTF-1), BD | Levels of TF-positive EVs were higher in patients with poor glycemic control than patients with good glycemic control | 75 |
| COVID-19 | EV | CD142-BV421 (HTF-1), BD | Levels of TF-positive EVs higher in patients with COVID-19 than in healthy controls | 76 |
| HIV | EV | CD142-APC (NY2), BioLegend | No difference in levels of TF-positive EVs between patients infected with HIV and uninfected controls | 77 |
| COVID-19 | Plasma | CD142-PE (HTF-1), BD | No difference in levels of TF-positive EVs between nonpregnant woman, healthy pregnant woman, and pregnant woman with COVID-19 | 78 |
| COVID-19 | Plasma | CD142-FITC, BioMedica Diagnostics | Levels of TF-positive EVs higher in patients with COVID-19 than in healthy controls | 79 |
| COVID-19 | EV | CD142-BV421 (HTF-1), BD | Levels of TF-positive EVs are higher in small EVs than in large EVs | 80 |
| COVID-19 | EV | CD142-FITC (VD8), BioMedica Diagnostics and CD142-PE (HTF-1), BD | Comparison of 2 anti-TF antibodies and fluorochrome-to-protein ratio in the detection of TF on EVs by FCM | 81 |
| COVID-19 | Plasma | CD142-PE (HTF-1), eBioscience | Levels of TF-positive EVs higher in patients with COVID-19 than in healthy controls | 82 |
| Cirrhosis and bacterial infection | Plasma | CD142 (IIID8), BioMedica Diagnostics and Alexa Fluor 750 (Sigma-Aldrich) | Patients with cirrhosis and bacterial infection had higher levels of TF-positive EVs than patients with cirrhosis without infection | 83 |
| Colorectal cancer | Plasma | CD142-PE (HTF-1), eBioscience | Levels of TF-positive EVs higher in patients with cancer than in controls | 84 |
| Disease/treatment . | Sample type . | TF antibody . | Results . | Reference . |
|---|---|---|---|---|
| Cancer | Plasma | CD142-PE (HTF-1), BD | Higher levels of TF-positive EVs in samples from patients with cancer compared with controls. Higher levels of TF-positive EVs in samples from patients with cancer with VTE compared with without VTE | 68 |
| Atorvastatin treatment | Plasma | CD142-PE (HTF-1), BD | Higher levels of TF-positive EVs during active treatment compared with nontreatment | 69 |
| Deep venous thrombosis | EV | CD142-FITC (VIC7), BioMedica Diagnostics | Higher levels of TF-positive EVs in samples from patients with VTE compared with controls | 70 |
| Statin therapy | EV | CD142-FITC (VD8), BioMedica Diagnostics | Statin therapy decreased the levels of TF-positive EVs | 71 |
| Lung cancer | Plasma | CD142-FITC, BioMedica Diagnostics | Levels of TF-positive EVs predicted distant metastasis | 72 |
| Cardiovascular risk | EV | CD142-FITC (VD8), BioMedica Diagnostics | Levels of TF-positive EVs correlated with lipid-rich atherosclerotic plaques | 73 |
| Cardiovascular risk | EV | CD142-FITC (VD8), BioMedica Diagnostics | Levels of TF-positive EVs were higher in patients with high cardiovascular risk than patients without risk | 74 |
| Type 2 diabetes | EV | CD142-PE (HTF-1), BD | Levels of TF-positive EVs were higher in patients with poor glycemic control than patients with good glycemic control | 75 |
| COVID-19 | EV | CD142-BV421 (HTF-1), BD | Levels of TF-positive EVs higher in patients with COVID-19 than in healthy controls | 76 |
| HIV | EV | CD142-APC (NY2), BioLegend | No difference in levels of TF-positive EVs between patients infected with HIV and uninfected controls | 77 |
| COVID-19 | Plasma | CD142-PE (HTF-1), BD | No difference in levels of TF-positive EVs between nonpregnant woman, healthy pregnant woman, and pregnant woman with COVID-19 | 78 |
| COVID-19 | Plasma | CD142-FITC, BioMedica Diagnostics | Levels of TF-positive EVs higher in patients with COVID-19 than in healthy controls | 79 |
| COVID-19 | EV | CD142-BV421 (HTF-1), BD | Levels of TF-positive EVs are higher in small EVs than in large EVs | 80 |
| COVID-19 | EV | CD142-FITC (VD8), BioMedica Diagnostics and CD142-PE (HTF-1), BD | Comparison of 2 anti-TF antibodies and fluorochrome-to-protein ratio in the detection of TF on EVs by FCM | 81 |
| COVID-19 | Plasma | CD142-PE (HTF-1), eBioscience | Levels of TF-positive EVs higher in patients with COVID-19 than in healthy controls | 82 |
| Cirrhosis and bacterial infection | Plasma | CD142 (IIID8), BioMedica Diagnostics and Alexa Fluor 750 (Sigma-Aldrich) | Patients with cirrhosis and bacterial infection had higher levels of TF-positive EVs than patients with cirrhosis without infection | 83 |
| Colorectal cancer | Plasma | CD142-PE (HTF-1), eBioscience | Levels of TF-positive EVs higher in patients with cancer than in controls | 84 |
APC, allophycocyanin; VTE, venous thromboembolism.